Serotype distribution among maternal and newborn colonizing Group B streptococcus isolates.

1<p>Molecular serotype identification by PCR was done by primers targeting serotypes 1a to V.</p

Demographics of the study population at time of enrolment (n = 661).

a<p>Data are no (%) of total participants, ^b,cData are row %.</p

Estimation of invasive potential of Group B streptococcus (GBS) serotypes in different countries.

<p>In our data two isolates of the same serotype (i.e III) were obtained from the same infant, and only one isolate was included in the analysis.</p>a<p>Value indicates colonizing isolates.</p>b<p>Value indicates neonatal invasive isolates.</p>c<p>Value in parenthesis indicates OR and 95% CI.</p>d<p>ND: No data for either invasive, colonization or both isolates.</p

Predictive value for 20–25, 26–30 and 31–35 weeks cultures in relation to culture status at 37+ weeks.

<p>PPV: Positive predictive value, NPV: Negative predictive value, CI-Confidence interval.</p

Association of pilus island proteins and serotypes among Group B <i>Streptococcus</i> isolates.

<p>Association of pilus island proteins and serotypes among Group B <i>Streptococcus</i> isolates.</p

Trial Profile.

<p>Trial Profile.</p

Serotype distribution among invasive disease isolates from early onset (EOS; <7 days of age), late onset diseases (LOD; 7 to 90 days of age) and in children older than 90 days.

1<p>Figure in squared parenthesis indicates number of isolates which were serologically non-reactive but typed by PCR.</p>2<p>Figure in rounded parenthesis is a percentage.</p

Univariate and multivariate association between serotype-specific colonization and observed demographic characteristics at enrolment.

<p>OR: odds ratio; AOR: adjusted OR; CI: confidence interval.</p

Proportion of infants with IgG concentrations of ≥ 35µg/ml following 2 and 3 doses of PCV-7.

<div><p>The proportion of infants with serum anti-capsular IgG antibody concentration ≥ 35µg/ml, a putative measure of protection against invasive pneumococcal disease, following vaccination with PCV-7. Vaccine was administered at 6,10 and 14 weeks of age or at 6,14 and 40 weeks of age. Antibody concentrations were assessed after the second and after the third dose in the series.</p> <p>PCV-7= 7-valent Pneumococcal Conjugate Vaccine, IgG = Immunoglobulin G.</p></div

Flow Diagram of study participation.

<div><p>Diagram indicating number of children enrolled into the study and number excluded or lost to follow-up during the course of the study.</p> <p>Withdrew consent = participant no longer wished to be part of study cohort and preferred to be vaccinated at local clinic. Relocated=participant moved out of study area and therefore unable to attend study visits. Lost to follow up = study site unable to contact study participant. Outside window period = vaccination occurred outside protocol defined period of 6-12 weeks; 12-24 weeks and 38-42 weeks for the first, second and third doses respectively. PCV= 7-valent Pneumococcal Conjugate Vaccine.</p></div